Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
13F holders, Q1 2025 (March 31)5holders +2
3new positions
1sold out
$0.90avg. 13F price*
At the end of Q1 2025, 5 institutions reported holding Bridgebio Pharma Inc. (bbio 2.25 02/01/29) in their 13F filings, up 2 from Q4 2024. 3 opened new positions and 1 sold out. The largest holders were HighTower Advisors, LLC ($3.6M), New York State Common Retirement Fund ($2.6M) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($2.3M).
- Company
- Bridgebio Pharma Inc. (bbio 2.25 02/01/29)
- CUSIP
- 10806XAD4
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $6.4M |
| Exits | 1 | $2.5M |
All 13F filers, Q4 2024 → Q1 2025: 7,118,000 shares bought and 2,000,001 shares sold, net +5,117,999 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| HighTower Advisors, LLC | 0.00% | New | 4,014,000 | $3.6M |
| New York State Common Retirement Fund | 0.00% | New | 2,871,000 | $2.6M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | Reduce 0.0% | 2,499,999 | $2.3M |
| Bank of New York Mellon Corp | 0.00% | New | 200,000 | $180K |
| Sei Investments Co. | 0.00% | Add +21.1% | 189,000 | $169K |
"% of holder's portfolio" is BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29)'s weight in each manager's 13F, not the share of Bridgebio Pharma Inc. (bbio 2.25 02/01/29) the manager owns.